Attached files
| file | filename |
|---|---|
| EX-10.06 - AMENDMENT TO ESCROW AGREEMENT AND DEFINITIVE AGREEMENTS - Mycotopia Therapies, Inc. | twgl_ex10z06.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 4, 2021
20/20 GLOBAL, INC. | ||||
(Exact name of registrant as specified in its charter) | ||||
|
|
|
|
|
Nevada |
| 000-56022 |
| 87-0645794 |
(State or other jurisdiction of |
| (Commission File Number) |
| (IRS Employer |
incorporation or organization) |
|
|
| Identification No.) |
|
|
|
|
|
480 22nd Street, Box 2 |
|
| ||
Heyburn, Idaho |
| 83336 | ||
(Address of principal executive offices) |
| (Zip code) | ||
|
|
| ||
Registrant’s telephone number, including area code: |
| Phone: (208) 312-7784 | ||
|
|
| ||
n/a | ||||
(Former name or former address, if changed since last report) | ||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
|
| ||
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
|
| ||
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
|
| ||
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||
|
| ||
Securities to be registered pursuant to Section 12(b) of the Act: | |||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |
None | None | None | |
| |||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter). Emerging growth company [ ] | |||
| |||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] | |||
ITEM 1.01 – ENTRY INTO MATERIAL DEFINITIVE AGREEMENTS
Effective January 4, 2021, 20/20 Global, Inc. entered into an Amendment to Escrow Agreement and Definitive Agreements to extend the closing date for each of the definitive agreements and the escrow agreement to a mutually agreeable date after completion of the audited financial statements of Mycotopia Therapies Inc. The parties also agreed to a corresponding extension of time for 20/20 Global to comply with Rule 14f-1 of the Securities Exchange Act.
ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
Exhibit Number* |
|
Title of Document |
|
Location |
|
|
|
|
|
10.06 |
|
| This filing |
_______________
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. Omitted numbers in the sequence refer to documents previously filed as an exhibit.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 20/20 GLOBAL, INC. | |
|
|
|
Dated: January 5, 2021 | By: | /s/ Mark D. Williams |
|
| Mark D. Williams, President, |
|
| Chief Executive Officer |
2